Exemptia 40mg Injection

Rheumatoid arthritis
Polyarticular juvenile idiopathic arthritis
Enthesitis-related arthritis
Ankylosing spondylitis
Axial spondyloarthritis without radiographic evidence of ankylosing spondylitis
Psoriatic arthritis
Plaque psoriasis
Hidradenitis suppurativa
Crohn’s disease
Ulcerative colitis
Non-infectious uveitis

The following are the possible side effects that can occur during your treatment with Adalimumab 40mg injection. Contact your medical practitioner immediately if any of the above-mentioned side effects appear.

Nausea

Injection site reactions

Headache

Back pain

Vomiting

Numbness

Muscle pain

Irregular heartbeat

Bruising

Ear congestion

Black or tarry stools

Sleep disturbances

Upper respiratory tract infection

EXEMPTIA 40mg Injection should be administered by a qualified nurse or medical professional, and the recommended dosage is decided by your doctor according to your medical history and current health conditions. In case of an overdose of EXEMPTIA 40mg Injection, contact your medical practitioner immediately to avoid severe side effects.

If you miss a dose of Adalimumab injection, contact your health professional as soon as possible. Try not to miss or skip your dosage of Exemptia injection.

 At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

Jani, R. H., Gupta, R., Bhatia, G., Rathi, G., Kumar, P. A., Sharma, R., Mendiratta, S. K. (2015). A prospective, randomized, double‑blind, multicentre, parallel‑group, active-controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC‑3197) and adalimumab (Humira) in patients with rheumatoid arthritis. International Journal of Rheumatic Diseases, 19(11), 1157–1168. https://doi.org/10.1111/1756-185X.12711.

Gharia, M., Kapoor, S., Kaushik, V. K., Jain, R., & Rao, V., et al. (2019). Real‑life Tolerability and effectiveness of adalimumab biosimilar in rheumatoid arthritis: ASPIRE registry data. Rheumatology and Therapy. https://doi.org/10.1007/s40744-019-0166-2

Kapoor, S., Kaushik, V. K., Jain, R., Rao, V. K. R., Gharia, M., et al. (2019). Real‑life tolerability and effectiveness of adalimumab biosimilar in ankylosing spondylitis: Adalimumab Biosimilar Patient Registry data. ACR Open Rheumatology, 1(8), 480–484. https://doi.org/10.1002/acr2.11067

Midha, Y., Kumar, N., Singhal, S., et al. (2023). Efficacy and safety of Exemptia™ (biosimilar adalimumab) in moderate-to-severe steroid-refractory ulcerative colitis: 24-week follow-up in a real-world setting. Biologics: Targets & Therapy (retrospective analysis). Patil, S. (2018). Low‑dose adalimumab biosimilar (ZRC‑3197) in the treatment of hidradenitis suppurativa. Indian Journal of Dermatology, Venereology and Leprology, 84(5), 745–747.